Gestational diabetes and metabolic dysfunction during pregnancy are serious concerns that warrant proactive management, but that management typically involves insulin, lifestyle modifications, and close glucose monitoring rather than GLP-1 compounds
Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is a GLP-1 receptor agonist that works primarily on metabolic pathways rather than immune function
Hall S, Isaacs D, Clements JN (2017) Pharmacokinetics and clinical implications of semaglutide: a new glucagonlike peptide (GLP)-1 receptor agonist
The Translational Gap: From Rodents to Humans Drug development typically moves from animal models to phased human trials
The mice in the NC group and PCOS group were subcutaneously injected with the same volume of physiological saline
[8] Keegan, S